Even though many challenges must be overcome before widespread adoption can occur, there is still much promise on the horizon for biosimilars.
Omar Hafez, MS, MBA
Advertisement
Articles by Omar Hafez, MS, MBA
Advertisement
Latest Updated Articles
Signs Point to Better Market Conditions for BiosimilarsPublished: September 5th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5